glp 1 agonists with cardiovascular benefit GLP-1 receptor agonists: The benefits beyond glucose control GLP-1 Muscle Loss Explained |
Description
Its cardiovascular safety in patients with cardiovascular disease or high cardiovascular risk was demonstrated in the aforementioned PIONEER-6 study.62 In the PIONEER 5 study, in patients with CKD stage 3, it was evaluated the efficacy and safety of a 14 mg dose, resulting superior to placebo in terms of reduction of HbA1c (-0.8% vs
P., Klingenberg, L., Astrup, A., & Sjdin, A
Normality of data distribution was determined by DAgostino and Pearson test normality test
Front Endocrinol 2021
Am J Physiol 275: G984-992, 1998
[DOI] [PubMed] [Google Scholar] Tibaduiza E
